Augmentation of oncology immunotherapies by pterostilbene containing compositions
Compositions and methods useful to enhancing, improving, or eliciting anti-tumor immune responses are disclosed. A pterostilbene containing composition is administered to a cancer patient at a sufficient concentration and frequency to induce de-repression of tumor targeting immune responses. The composition enhances antibody dependent cellular toxicity (ADCC) and augments efficacy of antigen specific immunotherapeutics such as trastuzumab and other monoclonal antibody therapies useful for treating cancer.
1. A method of treating cancer in a subject, comprising:
selecting a subject having a cancerous tumor; and
administering to the subject a composition comprising an effective amount of pterostilbene and IL-2.
2. The method of claim 1 , wherein the effective amount of pterostilbene is 25 μg/kg and wherein the effective amount of IL-2 is 500 IU.
3. The method of claim 1 , wherein the composition is administered orally or subcutaneously at least twice daily.
4. The method of claim 1 wherein the composition further comprises alpha lipoic acid.
5. The method of claim 1 wherein the composition further comprises superoxide dismutase (SOD).
6. The method of claim 1 wherein the composition further comprises 2-dimethylaminoethanol (DMAE).
7. The method of claim 1 wherein the composition further comprises piperine.
8. The method of claim 1 wherein the composition further comprises curcumin.